Streetbeat News

AVDL

Avadel Pharmaceuticals plc

https://www.avadel.com

Industry

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Open

11.76

Mkt cap

1.1B

Volume

1.6M

High

12.22

P/E Ratio

-15.55

52-wk high

19.09

Low

11.53

Div yield

N/A

52-wk low

10.41

Avadel Pharmaceuticals will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

Avadel Pharmaceuticals (NASDAQ:AVDL) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Greg Divis and CFO Tom McHugh, with analysts from Jefferies, Oppenheimer, H.C. Wainwright, Needham, and Piper Sandler attending.

Portfolio Pulse from

November 12, 2024 | 8:30 pm

HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 7:57 pm

Oppenheimer analyst Francois Brisebois has maintained an 'Outperform' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $29 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:20 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:15 pm

Tenon Medical, Avadel Pharmaceuticals, and Carvana shares are trading higher due to positive developments. Tenon Medical highlighted successful clinical data, Avadel won a court ruling favoring FDA approval of its drug, and Carvana reported strong Q3 results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:53 am

Avadel Pharmaceuticals' shares rose following a favorable U.S. District Court ruling in a lawsuit by Jazz Pharmaceuticals regarding the approval of Avadel's drug, LUMRYZ.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:27 am

Avadel Pharmaceuticals announced that the US District Court ruled in favor of the FDA in a lawsuit brought by Jazz Pharmaceuticals regarding the approval of LUMRYZ. The court upheld the FDA's decision that LUMRYZ is clinically superior to Jazz's oxybate products.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:25 am

Carvana Co. (NYSE:CVNA) shares surged over 20% in pre-market trading after reporting better-than-expected Q3 financial results, with revenue and earnings per share surpassing analyst estimates. Other notable pre-market movers include Root, Inc. (NASDAQ:ROOT) and Alphatec Holdings, Inc. (NASDAQ:ATEC), both rising significantly due to strong quarterly results.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 10:52 am

Avadel Pharmaceuticals and nference have published real-world data on narcolepsy, identifying demographic characteristics and prevalent comorbidities. The study, using Mayo Clinic Platform's AI software, offers comprehensive insights into narcolepsy patients.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.